Goldman Sachs Upgrades Hospira To Neutral

Analysts at Goldman Sachs upgraded

from Sell to Neutral. The price target for Hospira has been raised from $51 to $68. Hospira shares have surged 104.34% over the past 52 weeks, while the S&P 500 index has gained 14.77% in the same period. Hospira's shares jumped 35.25% to close at $87.64 yesterday.